Meiji Pharmaceutical University · Unclassified · 教授

Research keywordsHealth claims databases・Cost-effectiveness・ADHD prescribing・Rheumatoid arthritis biologics・Pancreatic cancer chemotherapy・Antimicrobial stewardship・Diabetic retinopathy risk・Hepatitis C utilities

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• [Trends in Spontaneous Adverse Event Reports Following the Expansion of Pembrolizumab Indications in Japan].2026
• [Survey of the Effect of Adding Aprepitant at the First Treatment of Regimens Containing Carboplatin on Antiemetic Efficacy].2026
• Longitudinal Changes in Utilities and HRQoL During Interferon‑Free DAA Therapy for Chronic Hepatitis C in Japan: Implications for Cost‑Utility Analysis2026
• Prescribing medications for attention-deficit/hyperactivity disorder in children: a retrospective analysis of a Japanese health insurance claims database.2026

• 薬剤耐性対策の費用対効果を適切に評価するための研究手法の開発2023
• 進行膵癌に対するがん化学療法の費用対効果に関する検討2019
• 薬剤耐性（AMR）による疾病負荷推計と抗菌薬適正使用の経済的有効性に関する検討2019
• 特殊な患者集団に対する添付文書の記載と情報に関する研究2015

• Official profile